Minimally Invasive Treatment for Prostate Cancer Receive Approval from FDA


Please Like and Share

Every year, around 220,000 men are diagnosed with prostate cancer across the world. The medical research teams around the world keep looking for innovative ways & treatments to help cure prostate cancer effectively. In the positive light, FDA has finally given approval for the non-surgical, minimally-invasive treatment for prostate cancer. The minimally-invasive treatment will be performed by the first-ever HIFU (High-Intensity Focused Ultrasound) device that has received the regulatory authorization from FDA for treating the prostate tissue ablation.

A leading French company named EDAP TMS –with its headquarters in Austin, USA has received the clearance from FDA (US Food & Drug Administration) for its high-tech HIFU device as the “Focal One”. Focal One will serve to be imparting the minimally-invasive treatment for prostate cancer by using the technology of high-intensity focused ultrasound.

A leading urologist named Brian Miles at the Methodist Hospital in Houston claims that this facility is going to be the first-ever in the US site for housing the given technology. With the help of the Focal One HIFU machine, the medical team at the Methodist Hospital in Houston is able to destroy the given target area of cancer cells instead of removing the entire prostate in the patients. As such, this process tends to reduce the overall risks of any potential side effects including urinary incontinence & erectile dysfunction. Men who suffer from localized prostate cancer (cancer only present in the prostate organ) are highly eligible for this minimally-invasive treatment.

The patients suffering from prostate cancer in the United States can now gain access to the minimally-invasive HIFU-empowered ultrasound treatments quite similar to the one delivered by Focal One. These are Sonablate from SonaCare and Ablatherm from EDAP.